Search

everythinglearnresearchcommunity

for

Search:↓

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

The user noticed hair regrowth after 4 years of hair loss, coinciding with lifestyle improvements like quitting smoking, exercising, and a better diet. They are curious if dormant follicles can recover under improved conditions.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

RU58841 had mixed results for hair regrowth, with some users experiencing no change and others noting regrowth but also side effects like libido issues and chest pain. Some users combined it with other treatments like finasteride and dutasteride, with varying effectiveness.

The conversation discusses aggressive hair loss treatments, including finasteride, dutasteride, minoxidil, topical cetirizine, and experimental options like Estrogel, oh-flutamide, and RU58841. Users share experiences and suggest trying oral minoxidil and el cranell, noting the complexity and challenges of treating hair loss.

The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.

The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.

2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.

Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

User TH1RT33N_DR34M shares that MinoxidilMax plans to make topical Procyanidin B2 within a month. Users discuss the legitimacy of the product, quality control, and potential results from using it for hair loss.

The user is experiencing some hair regrowth after 3 months of using finasteride, minoxidil, biotin, vitamin C, and vitamin D, with noticeable improvements in hair thickness and baby hairs on the hairline. Other users suggest additional treatments like dermarolling and scalp massages for better results.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

Dutasteride and high-dose Minoxidil are the primary treatments maintaining hair, with additional supplements and therapies like red light offering minimal extra benefit. The discussion criticizes promoting expensive hair care products when basic medications are doing most of the work.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

Alfatradiol helps reduce hair shedding and itching, and is effective for mild hair loss. Users combine it with treatments like fluridil, minoxidil, and sometimes consider finasteride.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.

The conversation is about the release of Phase 3 trial results for pyrilutamide in China for treating hair loss. The user is inquiring if the actual results have been posted, noting that a recent release did not contain them.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.